19 November 2025 The court rules that Duke University and Allergan’s patent lacked sufficient written description, in the wake of stricter post-Amgen Section 112 standards.
18 November 2025
18 November 2025
17 November 2025
14 November 2025
Latest Features
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
From setting a clear overall strategy to drafting high-quality claims, Christopher Wheeler and Gerald Murphy of Birch, Stewart, Kolasch & Birch explain how to reduce patent prosecution expenditure and obtain better IP protection.
Asia
Hui Zhuang of CCPIT Patent and Trademark Law Office discusses several strategies to increase the chance of pharmaceutical or food trademarks that include ingredients being registered.
Latest Conference Videos
Unified Patent Court
Powell Gilbert experts share insights on how the Unified Patent Court is taking shape after two years in operation, in this session from LSPN.
Americas
This LSPN panel brings together experts from Troutman Pepper Locke, Sauvegarder Investment Management, Beam Therapeutics, Editas Med, and Takeda to explore the expanding role of IP lawyers in the life sciences industry.
Americas
Jennifer Che of Eagle IP explores key IP challenges in China and offers practical strategies to address them, covering topics such as AI, patent linkage and export controls in this LSPN session.
Americas
This LSPN session features experts from EIP, The Broad Institute of MIT and Harvard, Pfizer, and an independent specialist discussing the protection of life science innovations involving big data, AI, and machine learning.
More News
13 November 2025 Pharma company tells court generics rival’s petition is “not the subject of any legal conflict”, as it reassures investors that a $12bn biotech acquisition will deliver growth.
13 November 2025 US Federal Trade Commission’s antitrust warning tipped the scales in Pfizer’s favour, ending a heated dispute over a weight-loss biotech.
13 November 2025 Regeneron’s Adam Gastonguay shares how to raise the profile of your IP team, get the most from outside counsel, and stay ahead of the growing pressure to adopt AI.
11 November 2025 Partnering with AI vendors can open doors for startups and small companies but it also brings serious risks. Experts at AI & IP Europe share key lessons on contracts, data ownership, ring-fencing, monitoring, and exit planning, as Marisa Woutersen reports.
11 November 2025 Cosmetics companies are increasingly using biological molecules in product applications but will need to draft patent applications carefully in this ‘grey area’.
10 November 2025 According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.
7 November 2025 The ‘distinguished litigator’ rejoins six former colleagues at the new firm, bringing expertise in high-stakes disputes representing global tech and life sciences clients.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox